LKT Labs

Biochemicals for Life Science Research

NVP-AUY922

Product ID N8660
Cas No. 747412-49-3
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $75.00 In stock
5 mg $120.00 In stock
10 mg $200.00 In stock
Bulk Quote

Quicklinks

Description

NVP-AUY922 is an isoxazole-based inhibitor of heat shock protein 90 (HSP90) that displays anticancer chemotherapeutic and anti-angiogenic activities. NVP-AUY922 inhibits cell growth in pancreatic and colorectal cancer cells. In adult T-cell leukemia cells, NVP-AUY922 induces G1 phase cell cycle arrest and apoptosis, suppressing cell growth. Additionally, this compound induces tumor regression and decreases microvessel density in animal models of breast cancer, ovarian cancer, prostate cancer, and melanoma.

Product Info

Cas No.

747412-49-3
Purity

≥98%
Formula

C26H31N3O5
Formula Wt.

465.54
IUPAC Name

5-(2,4-Dihydroxy-5-isopropylphenyl)-N-ethyl-4-[4-(4-morpholinylmethyl)phenyl]-1,2-oxazole-3-carboxamide
Synonym

VER-52296, Luminespib, AUY922
Solubility

DMSO 93 mg/mL warmed (199.76 mM) Ethanol 31 mg/mL (66.58 mM) Water Insoluble
Appearance

White to off white powder

Shipping and Storage

Store Temp

-20°C
Ship Temp

Ambient

Downloads

MSDS

N8660 MSDS PDF
Info Sheet

N8660 Info Sheet PDF

References

Kim SH, Kang JG, Kim CS, et al. Novel Heat Shock Protein 90 Inhibitor NVP-AUY922 Synergizes With the Histone Deacetylase Inhibitor PXD101 in Induction of Death of Anaplastic Thyroid Carcinoma Cells. J Clin Endocrinol Metab. 2015 Feb;100(2):E253-61. PMID: 25389633.

Taniguchi H, Hasegawa H, Sasaki D, et al. Heat shock protein 90 inhibitor NVP-AUY922 exerts potent activity against adult T-cell leukemia-lymphoma cells. Cancer Sci. 2014 Dec;105(12):1601-8. PMID: 25263741.

Eccles SA, Massey A, Raynaud FI, et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res. 2008 Apr 15;68(8):2850-60. PMID: 18413753.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • N5766

    L-(-)-Norepinephrine Bitartrate Monohydrate

    Endogenous hormone and neurotransmitter involve...

    ≥98%
  • E4902

    Emamectin B1 Benzoate

    Semi-synthetic avermectin; GABA potentiator.

    ≥80%
  • A1332

    Adipokinetic Hormone II from Locusta migratoria

    Neuropeptide found in Locusta migratoria.

    ≥98%
  • H965142

    Hydrolyzed Fumonisin B1

    Mycotoxin produced by Fusarium fungi that infec...

    ≥99% by ELSD
  • N3322

    Niflumic Acid

    NSAID; NMDA inverse agonist, T-type Ca2+ and Cl...

    ≥98%
  • D3209

    Diclofenac Sodium

    NSAID; COX-1/2 inhibitor, potential K+ channel ...

    ≥99%
  • F0048

    Famciclovir

    Penciclovir prodrug, nucleoside (guanosine) ana...

    ≥98%
  • N3301

    Niacin

    Vitamin B, required for formation of NAD and NA...

    ≥98%
  • L1628

    Ac-LEHD-pNa

    Caspase 9 substrate.

    ≥95%
  • T5946

    Toltrazuril

    Coccidiostat; mitochondrial respiration inhibit...

    ≥98%
  • A5161

    Ampiroxicam

    Piroxicam prodrug, NSAID; COX-1/2 inhibitor.

    ≥98%
  • P2858

    4-α-Phorbol-12-myristate-13-acetate

    Negative control for PKC activation.

    ≥98%
  • P2100

    PF-06447475

    LRRK2 inhibitor.

    ≥98%
  • B6935

    Brivudine

    Nucleoside (thymidine) analog; DNA chain termin...

    ≥98%
  • G7346

    GSK-2636771

    p110β PI3K inhibitor.

    ≥98%
  • A4931

    3-Aminobenzamide

    PARP inhibitor.

    ≥97%
  • S0225

    SAG Dihydrochloride

    Smoothened agonist.

    ≥98%
  • G1721

    Gefitinib

    EGFR inhibitor.

    ≥98%
  • E8419

    Everolimus

    mTORC1 inhibitor.

    ≥98%
  • C0254

    Candesartan Celexetil Ester

    AT1 inhibitor.

    ≥98%